Medication for OCD: What SSRIs and Other Options Do

SSRIs treat OCD, but not the way most people expect.

If you have been started on an SSRI for OCD and told to wait six weeks and see how you feel, you may have received incomplete guidance. OCD medication requires a different framework: higher doses, longer trials, and in many cases a sequenced approach across multiple agents before the right fit is found.

Understanding what the medications actually do, and how OCD medication differs from depression medication in practical terms, changes how you work with your prescriber and how patiently you wait for the evidence to come in.

What This Page Covers

• Why SSRIs are the first-line treatment for OCD and which ones are FDA-approved
• Why OCD requires higher doses and longer trials than depression
• What clomipramine is, how it compares to SSRIs, and when it is used
• What happens when SSRIs do not produce sufficient response
• Augmentation options, including antipsychotics and ERP therapy
• How OCD medication and behavioral therapy work together

Why SSRIs Work for OCD

OCD affects approximately 2 to 3 percent of individuals worldwide and is marked by recurrent, distressing intrusive thoughts (obsessions) and repetitive behaviors (compulsions). The underlying mechanism involves dysregulation in cortico-striato-thalamo-cortical circuits, with serotonergic dysfunction playing a central role.

The medications that work for OCD are, with one important exception, serotonin reuptake inhibitors (SRIs). This includes the SSRIs and clomipramine, a tricyclic antidepressant that functions as a potent SRI. The only medications currently approved by the FDA for OCD are serotonin reuptake inhibitors, and with a favorable side effect profile relative to clomipramine, SSRIs are currently the first-line pharmacotherapy.

Which SSRIs Are FDA-Approved for OCD

Five SSRIs have direct clinical evidence supporting their use in OCD:

• Fluoxetine (Prozac)
• Fluvoxamine (Luvox)
• Sertraline (Zoloft)
• Paroxetine (Paxil)

Two others, citalopram and escitalopram, are not FDA-approved for adults with OCD but are supported by clinical evidence and used in practice.

All the SSRIs and clomipramine appear to be equally effective for the treatment of OCD, according to the International OCD Foundation’s treatment guide. The choice between SSRIs is based on side effect profile, drug interactions, patient and family history of response, and patient preference, not on differential efficacy.

A common myth is that fluvoxamine (Luvox) is more effective for OCD than other SSRIs. This myth began when fluvoxamine became the first SSRI marketed specifically for OCD. Head-to-head trials found that all the SSRIs had very similar efficacy.

OCD Medication Is Different from Depression Medication

The most important thing for patients to understand about SSRI treatment for OCD is this: the rules are different from depression.

Higher doses. Studies have shown that, on average, dosages of SSRIs up to two to three times higher than those typically used for depression and anxiety disorders yield the greatest benefits for OCD. For example, fluoxetine may be prescribed at 60 to 80 mg or higher for OCD, compared to 20 to 40 mg for depression.

Longer trials. An adequate trial of an SSRI for OCD requires 8 to 12 weeks, with at least 6 of those weeks at the moderate to high doses required for effective treatment. This is longer than the 4 to 6 week trials that indicate response for depression. One of the most common causes of apparent treatment resistance in OCD is prematurely discontinuing an SSRI before an adequate trial is complete.

Slower response. Initial improvement in OCD symptoms may not be apparent until 4 to 6 weeks of treatment, with maximum benefit taking considerably longer. Most patients notice some benefit after 3 to 4 weeks, while maximum benefit should occur between 12 weeks and 6 months of treatment at an adequate dose.

Clomipramine: The Original OCD Medication

Before SSRIs existed, clomipramine (Anafranil) was the treatment. Clomipramine was the first medication to be found effective for treating OCD, and the first medication FDA-approved for OCD, in 1989. It works primarily through potent serotonin reuptake inhibition, which is what makes it unique among tricyclic antidepressants.

The question of whether clomipramine is more effective than SSRIs for adults with OCD has been thoroughly researched. There does not appear to be substantive evidence that clomipramine is any more effective than SSRIs. Head-to-head trials showed the SSRIs and clomipramine had equal efficacy for OCD. Some meta-analyses have suggested marginal numerical superiority for clomipramine, but this has not been consistently replicated.

Clomipramine’s side effect profile limits its use as a first-line agent. Compared to SSRIs, clomipramine is associated with greater side effect burden, including anticholinergic effects such as dry mouth and constipation, antihistaminergic effects such as sedation and weight gain, and arrhythmogenic potential that necessitates EKG monitoring. For these reasons, most clinical guidelines recommend trying at least two SSRIs before moving to clomipramine.

When SSRIs Do Not Produce Adequate Response

Studies demonstrate response rates of up to 60 percent with SSRI treatment for OCD. That means roughly 40 percent of people will not have a sufficient response to their first SSRI. When this happens, there is an evidence-based sequence to follow.

Step 1: Optimize. Confirm the dose is at the high end of the therapeutic range for OCD (not just the FDA maximum for depression) and that the trial has been genuinely adequate. Many apparent non-responders have not reached an adequate dose or duration.

Step 2: Switch. Trying a different SSRI before concluding SSRIs have failed is often productive. Patients will often have a positive response to the second SSRI, though it appears to be 10 to 20 percent less likely than the first trial. Another SSRI is typically the first switch; clomipramine comes after two to three failed SSRI trials.

Step 3: Augment. When an SSRI produces partial but insufficient response, adding a second medication can help. The most evidenced-based augmentation strategy for OCD is to add low-dose aripiprazole or risperidone, both atypical antipsychotics used here at much lower doses than for psychosis. Approximately one-third of patients who do not have satisfactory responses to an SSRI alone will respond when a low-dose antipsychotic is added.

Step 4: Add ERP. Research increasingly shows that behavioral therapy can be more powerful than pharmacological augmentation. Studies indicate that ERP is more effective than risperidone augmentation for treatment-resistant OCD. If ERP has not been pursued at high intensity, adding or intensifying it often produces greater benefit than switching or adding medications.

Medication and ERP: Better Together

For most people with OCD, the combination of medication and ERP produces better outcomes than either alone.

CBT with exposure and response prevention can be a first-line treatment for OCD and is an alternative to SSRIs. Medication can make ERP more accessible by reducing the baseline anxiety and hyperarousal that makes confronting feared triggers harder. ERP helps the brain learn that feared consequences do not occur, addressing OCD more directly at the level of behavior and cognition.

No single approach works best for everyone with OCD, although most people probably do best with CBT plus an SRI. The medication’s job is to make the therapeutic work more accessible, not to replace it.

About SiggyMD

OCD frequently co-occurs with depression and anxiety disorders. For many people with OCD, managing these co-occurring conditions with consistent clinical oversight changes the daily baseline of function, and makes the demanding work of ERP therapy more accessible.

“One of the most underappreciated parts of OCD care is the co-occurring depression and anxiety that come alongside it,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “When someone is in the middle of an OCD struggle, their depression is often also untreated and making everything harder. Getting the serotonergic medication right, monitoring it consistently, adjusting when side effects emerge: that is the foundation the rest of the treatment builds on. Our daily check-in model lets us see what is actually happening between visits, which changes how quickly we can optimize the medication picture.”

SiggyMD provides clinician-supervised SSRI management for anxiety and depression, with daily check-ins that build a longitudinal picture of how the medication is working over time. For OCD-specific ERP therapy, a therapist trained in exposure and response prevention is the appropriate clinical resource. For the depression and anxiety that frequently accompany OCD, SiggyMD provides continuous, clinician-reviewed SSRI management.

No name, no email, no account required to start. A licensed prescriber reviews every treatment plan.

For more on OCD, see our guides on what OCD is, types of OCD, and how to treat OCD.

Start your anonymous intake with SiggyMD.

What Members Are Saying

DR

D.R., 38

OCD with Co-Occurring Anxiety and Depression

“I had been on the same SSRI at a low dose for years. No one ever explained that OCD needs different dosing. When my new prescriber adjusted the dose and we actually waited the full 12 weeks, the outcome was completely different. I wish someone had told me this sooner.”

ML

M.L., 29

OCD, Switched to Clomipramine After Two SSRIs

“The side effects from clomipramine were real, the dry mouth and sedation especially. But my prescriber had told me exactly what to expect, and we monitored it carefully. For me, after two SSRIs that didn’t move the needle enough, it worked. Having someone tracking how I was doing weekly made the difference in staying with it.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

If you are in crisis or experiencing thoughts of self-harm, call or text 988. If you are in immediate danger, call 911.

Sources

1. International OCD Foundation. Medication. IOCDF Treatment Guide.

2. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatric Clinics of North America. 2014;37(3):375-391.

3. Fineberg NA, et al. Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder. Pharmacopsychiatry. 2020;53(04):167-188.

4. Issari Y, et al. Moving beyond first-line treatment options for OCD. Mental Health Clinician. 2022;12(6):381.

5. National Institute of Mental Health. Obsessive-Compulsive Disorder (OCD). NIMH. Reviewed 2024.

6. Srivastava S, et al. Optimal Dose of Serotonin Reuptake Inhibitors for Obsessive-Compulsive Disorder in Adults: A Systematic Review and Dose-Response Meta-Analysis. Frontiers in Psychiatry. 2021;12:717999.

7. University of Florida Department of Psychiatry. Medications for OCD. UF OCD and Anxiety Disorders Treatment Program.

8. Bose A, et al. Clomipramine - StatPearls. NCBI Bookshelf. Updated 2023.